José M Castellano1, Ginés Sanz2, José L Peñalvo2, Sameer Bansilal3, Antonio Fernández-Ortiz4, Luz Alvarez2, Luis Guzmán5, Juan Carlos Linares5, Fernando García6, Fabiana D'Aniello6, Joan Albert Arnáiz7, Sara Varea7, Felipe Martínez8, Alberto Lorenzatti8, Iñaki Imaz9, Luis M Sánchez-Gómez9, Maria Carla Roncaglioni10, Marta Baviera10, Sidney C Smith11, Kathryn Taubert11, Stuart Pocock12, Carlos Brotons13, Michael E Farkouh14, Valentin Fuster15. 1. Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III, Madrid, Spain; Icahn School of Medicine at Mount Sinai, New York, New York. 2. Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III, Madrid, Spain. 3. Icahn School of Medicine at Mount Sinai, New York, New York. 4. Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III, Madrid, Spain; Hospital Clínico San Carlos, Madrid, Spain. 5. Federación Argentina de Cardiología, Córdoba, Argentina. 6. FERRER Internacional, Barcelona, Spain. 7. Fundació Clinic per la Recerca Biomèdica, Barcelona (FCRB), Spain. 8. Instituto DAMIC, Cordoba, Argentina. 9. Instituto de Salud Carlos III (ISCIII), Madrid, Spain. 10. Istituto di Ricerche Farmacologiche "Mario Negri" (IRFMN) Milan, Italy. 11. World Heart Federation (WHF), Geneva, Switzerland. 12. Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III, Madrid, Spain; London School of Hygiene and Tropical Medicine, London, United Kingdom. 13. Equip d'Atenció Primària Sardenya-Institut d'Investigacions Biomèdiques Sant Pau, Barcelona, Spain. 14. Peter Munk Cardiac Centre, University Health Network, Toronto, Ontario, Canada. 15. Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III, Madrid, Spain; Icahn School of Medicine at Mount Sinai, New York, New York. Electronic address: valentin.fuster@mountsinai.org.
Abstract
BACKGROUND:Adherence to evidence-based cardiovascular (CV) medications after an acute myocardial infarction (MI) is low after the first 6 months. The use of fixed-dose combinations (FDC) has been shown to improve treatment adherence and risk factor control. However, no previous randomized trial has analyzed the impact of a polypill strategy on adherence in post-MI patients. OBJECTIVES: The cross-sectional FOCUS (Fixed-Dose Combination Drug for Secondary Cardiovascular Prevention) study (Phase 1) aimed to elucidate factors that interfere with appropriate adherence to CV medications for secondary prevention after an acute MI. Additionally, 695 patients from Phase 1 were randomized into a controlled trial (Phase 2) to test the effect of a polypill (containing aspirin 100 mg, simvastatin 40 mg, and ramipril 2.5, 5, or 10 mg) compared with the 3 drugs given separately on adherence, blood pressure, and low-density lipoprotein cholesterol, as well as safety and tolerability over a period of 9 months of follow-up. METHODS: In Phase 1, a 5-country cohort of 2,118 patients was analyzed. Patients were randomized to either the polypill or 3 drugs separately for Phase 2. Primary endpoint was adherence to the treatment measured at the final visit by the self-reported Morisky-Green questionnaire (MAQ) and pill count (patients had to meet both criteria for adherence at the in-person visit to be considered adherent). RESULTS: In Phase 1, overall CV medication adherence, defined as an MAQ score of 20, was 45.5%. In a multivariable regression model, the risk of being nonadherent (MAQ <20) was associated with younger age, depression, being on a complex medication regimen, poorer health insurance coverage, and a lower level of social support, with consistent findings across countries. In Phase 2, the polypill group showed improved adherence compared with the group receiving separate medications after 9 months of follow-up: 50.8% versus 41% (p = 0.019; intention-to-treat population) and 65.7% versus 55.7% (p = 0.012; per protocol population) when using the primary endpoint, attending the final visit with MAQ = 20 and high pill count (80% to 110%) combined, to assess adherence. Adherence also was higher in the FDC group when measured by MAQ alone (68% vs. 59%, p = 0.049). No treatment difference was found at follow-up in mean systolic blood pressure (129.6 mm Hg vs. 128.6 mm Hg), mean low-density lipoprotein cholesterol levels (89.9 mg/dl vs. 91.7 mg/dl), serious adverse events (23 vs. 21), or death (1, 0.3% in each group). CONCLUSIONS: For secondary prevention following acute MI, younger age, depression, and a complex drug treatment plan are associated with lower medication adherence. Meanwhile, adherence is increased in patients with higher insurance coverage levels and social support. Compared with the 3 drugs given separately, the use of a polypill strategy met the primary endpoint for adherence for secondary prevention following an acute MI. (Fixed Dose Combination Drug [Polypill] for Secondary Cardiovascular Prevention [FOCUS]; NCT01321255).
RCT Entities:
BACKGROUND: Adherence to evidence-based cardiovascular (CV) medications after an acute myocardial infarction (MI) is low after the first 6 months. The use of fixed-dose combinations (FDC) has been shown to improve treatment adherence and risk factor control. However, no previous randomized trial has analyzed the impact of a polypill strategy on adherence in post-MI patients. OBJECTIVES: The cross-sectional FOCUS (Fixed-Dose Combination Drug for Secondary Cardiovascular Prevention) study (Phase 1) aimed to elucidate factors that interfere with appropriate adherence to CV medications for secondary prevention after an acute MI. Additionally, 695 patients from Phase 1 were randomized into a controlled trial (Phase 2) to test the effect of a polypill (containing aspirin 100 mg, simvastatin 40 mg, and ramipril 2.5, 5, or 10 mg) compared with the 3 drugs given separately on adherence, blood pressure, and low-density lipoprotein cholesterol, as well as safety and tolerability over a period of 9 months of follow-up. METHODS: In Phase 1, a 5-country cohort of 2,118 patients was analyzed. Patients were randomized to either the polypill or 3 drugs separately for Phase 2. Primary endpoint was adherence to the treatment measured at the final visit by the self-reported Morisky-Green questionnaire (MAQ) and pill count (patients had to meet both criteria for adherence at the in-person visit to be considered adherent). RESULTS: In Phase 1, overall CV medication adherence, defined as an MAQ score of 20, was 45.5%. In a multivariable regression model, the risk of being nonadherent (MAQ <20) was associated with younger age, depression, being on a complex medication regimen, poorer health insurance coverage, and a lower level of social support, with consistent findings across countries. In Phase 2, the polypill group showed improved adherence compared with the group receiving separate medications after 9 months of follow-up: 50.8% versus 41% (p = 0.019; intention-to-treat population) and 65.7% versus 55.7% (p = 0.012; per protocol population) when using the primary endpoint, attending the final visit with MAQ = 20 and high pill count (80% to 110%) combined, to assess adherence. Adherence also was higher in the FDC group when measured by MAQ alone (68% vs. 59%, p = 0.049). No treatment difference was found at follow-up in mean systolic blood pressure (129.6 mm Hg vs. 128.6 mm Hg), mean low-density lipoprotein cholesterol levels (89.9 mg/dl vs. 91.7 mg/dl), serious adverse events (23 vs. 21), or death (1, 0.3% in each group). CONCLUSIONS: For secondary prevention following acute MI, younger age, depression, and a complex drug treatment plan are associated with lower medication adherence. Meanwhile, adherence is increased in patients with higher insurance coverage levels and social support. Compared with the 3 drugs given separately, the use of a polypill strategy met the primary endpoint for adherence for secondary prevention following an acute MI. (Fixed Dose Combination Drug [Polypill] for Secondary Cardiovascular Prevention [FOCUS]; NCT01321255).
Authors: Ehete Bahiru; Angharad N de Cates; Matthew Rb Farr; Morag C Jarvis; Mohan Palla; Karen Rees; Shah Ebrahim; Mark D Huffman Journal: Cochrane Database Syst Rev Date: 2017-03-06
Authors: Alejandra Soto; Ximena Avila; Pia Cordova; Pola Fernandez; Mariela Lopez; Lorenzo A Villa; Felipe Morales Journal: Int J Clin Pharm Date: 2015-05-26
Authors: P Bramlage; W März; D Westermann; B Weisser; J H Wirtz; U Zeymer; P Baumgart; G van Mark; U Laufs; B K Krämer; T Unger Journal: Herz Date: 2017-03-24 Impact factor: 1.443
Authors: Diann E Gaalema; Rebecca J Elliott; Zachary H Morford; Stephen T Higgins; Philip A Ades Journal: Prog Cardiovasc Dis Date: 2017-01-05 Impact factor: 8.194
Authors: Mieke L van Driel; Michael D Morledge; Robin Ulep; Johnathon P Shaffer; Philippa Davies; Richard Deichmann Journal: Cochrane Database Syst Rev Date: 2016-12-21